Results 221 to 230 of about 28,326 (256)
Some of the next articles are maybe not open access.
Enrichment and Analysis of ctDNA
2019ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire +3 more sources
ctDNA: Moving toward Clinical Utility
Cancer Discovery, 2022Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire +2 more sources
Review ctDNA and Breast Cancer
2019In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely fundamental research to nearby daily use for treatment selection and drug-resistance assessment. Indeed, technical advances and widespread use of next-generation sequencing or digital PCR allowed for detection of very low amount of tumor DNA in bloodstream.
openaire +3 more sources
Dynamic Treatment Stratification Using ctDNA
2019An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana, Vidal +2 more
openaire +2 more sources
Abstract LB106: Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy
Cancer ResearchAbstract Mononucleosomal ctDNA (mnctDNA, 157-bp, double-stranded) spearheads liquid biopsy (LB) for cancer detection, treatment and clinical care. The bottleneck of mnctDNA LB are low copy number of ctDNA and limit of detection of platform technologies.
Feng Li +8 more
openaire +1 more source
Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Cancer Discovery, 2021Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of ...
openaire +2 more sources
Technical and biological constraints on ctDNA-based genotyping
Trends in Cancer, 2021Cameron Herberts, Alexander W Wyatt
exaly